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Abstract 
Objective
Transforming growth factor-beta (TGF-β), a group of multifunctional 
growth factors, plays an important role in the neuron survival and 
neurodevelopmental functions. Some studies have evaluated the 
correlation between TGF-β1 and TGF-β2 abnormalities and autism 
spectrum disorders. In this study, we compared the TGF-β1 and 
TGF-β2 levels between autistic and intellectually normal individuals. 
Materials & Methods
 The study population consisted of 39 autistic and 30 age-matched 
intellectually normal individuals (control group). Blood samples 
were taken from all individuals, and all patients were divided into 
2 groups (mild-to-moderate and severe) according to the childhood 
autism rating scale. The cytokines levels were measured by Enzyme 
Linked Immunosorbent Assay (ELISA). 
Results 
The mean concentration of TGF-β1 was significantly lower (P 
< 0.0001) in children with autism compared to the control group 
(25.3 ± 6.5 versus 35.1 ± 9.4 ng/mL, respectively). Also, the mean 
concentration of TGF-β2 in children with autism (32.35± 7.75 ng/
mL) was higher compared to those in the control group (30.47± 4.36 
ng/mL); however, this difference did not reach statistical significance 
(P = 0.21). A positive correlation was observed between TGF-β1 
concentration and autism severity (r = 0.41; P = 0.02), whereas a 
negative correlation was found between TGF-β2 concentration and 
autism severity (r = -0.41; P = 0.02).
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Introduction
Childhood autism, characterized by stereotypical 
behaviors, and social and communication 
impairments, is a condition with neurodevelopmental 
etiology that occurs under 3 years of age (1, 2). 
The prevalence of this disorder has increased 
considerably over the past 3 decades. Many of 
the recent epidemiological reviews estimate a 
prevalence of 1 per 88 children in the United States 
(3). Although the exact nature of autism is still not 
fully understood, genetic abnormalities, perinatal 
events (e.g. vaginal bleeding after the first trimester, 
presence of meconium in amniotic fluid, respiratory 
distress syndrome, and anemia in neonatal period), 
neuroanatomical abnormalities (e.g. enlargement 
of occipital, parietal, and temporal lobes), and 
biochemical factors (e.g. hyperserotonemia in the 
presence of mental retardation) are proposed to 
play a role in the pathophysiology of this condition 
(4). 
It has been hypothesized that some mechanisms of 
autism act through inflammatory, oxidative, and 
autoimmune processes (5, 6). In addition, it has 
been proposed that immunological factors have a 
key role in the pathophysiology of this condition 
(7). Several previous studies have illustrated a 
correlation between abnormalities of the immune 
system and autism spectrum disorders (ASDs). 
These immune system abnormalities may include 
abnormalities in the functional immune cell subsets 
and autoimmunity caused by inappropriate immune 
regulation such as autoantibodies generated against 
the central nervous system (CNS) (8, 9). It has been 
assumed that the development of neurological 
disorders may be caused by the abnormal immune 
responses during the critical neurodevelopmental 
period (10). The validity of the hypothesis of the 
immune system abnormalities in autistic patients 
has been derived from the critical role of the 
immune system in neurodevelopment and the 
ability of these changes to influence the CNS 
(10, 11). Both the immune and nervous systems 
are evolved systems that cross-talk via cytokines 
and neuromediators such as neuropeptides (12). 
Changes in the ratios of excitatory to inhibitory 
signaling in the brain may also contribute to ASD 
(13).
Immune mediators, known as cytokines, are 
the main facilitators of the cross-systemic 
communication. Cytokines, a broad category of 
small proteins, control the duration, nature, and 
intensity of an immune response. In addition, 
cytokines serve as a common language between 
the immune and the CNS (14). These mediators 
are essential in maintaining the normal aspects 
of neurodevelopment, such as progenitor cell 
Conclusion 
The results of the present investigation suggest that there is a decrease 
in the levels of TGF-β1 in the serum of patients with autism and this 
cytokine may be effective in the treatment of the pathophysiological 
aspects of autism.
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differentiation, cellular localization/migration 
within the CNS, and synaptic network formation, 
thus influencing both the developmental and 
functional aspects of the nervous system (15). 
Furthermore, neuroimmune interactions are highly 
diverse and vary between individuals (16). For 
example, the impact of the cytokines differ between 
the developing brain and the adult brain, and 
each require cytokines in different concentrations 
(15). Therefore, imbalanced cytokine production, 
signaling, and/or regulation may induce a wide 
range of neurological complications. Imbalances 
in the level of cytokine during development could 
affect neural activity and mediate behavioral 
disorders such as autism. In the following, we 
investigate the significance of several cytokines 
linked to ASD (14). Cytokine abnormalities in 
ASD are an important indication resulting from 
environmental and genetic factors, and may 
directly contribute to neurological dysfunctions 
(8, 14). However, the relationship between the 
neurological and immunological functions has not 
been highlighted enough (17). 
TGF-β has a role to play in the immune system 
in addition to controlling proliferation, cellular 
differentiation, and other functions in the majority 
of cells (18). This cytokine exists in at least 3 
isoforms: TGF-β1, TGF-β2, and TGF-β3 (19). 
Compared to other anti-inflammatory cytokines 
such as IL-10, higher expression of the genes 
encoding TGF-β exists in most tissues (20). 
TGF-β1 is an important immune regulator for 
immune homeostasis and orchestrates aspects of 
embryonic development (21). It has been suggested 
that TGF-β1 has an important regulatory role in 
CNS development and has potential implications 
for neurogenesis in a variety of TGF-β1-related 
CNS diseases (14, 15). Some investigators also 
found that TGF-β1 plays a crucial, suppressive 
role in early CNS development and has a major 
role in neuronal migration, survival, and synapse 
formation (22). Also, a TGF-β1 knockout mouse has 
been shown to have severe cortical developmental 
impairment with pervasive increased neuronal cell 
death and microgliosis complications; therefore, 
it is vital for proper neurodevelopment (23). 
However, the aforementioned investigations 
propose that immune system aberrations may 
cause abnormal immune responses, autoimmunity, 
or adverse neuroimmune interactions during 
brain development (22, 24). Several studies have 
demonstrated decreased TGF-β1 levels in the sera 
and cerebrospinal fluid (CSF) of autistic children 
(25, 26). Additionally, decreased levels of TGF-β1 
in serum have been reported in autistic children 
(25). However, it remains unclear whether the 
serum levels of TGF-β1and TGF-β2 reflect their 
levels in the brain (26).
Many of the previous findings suggest that 
decreased levels of TGF-β1 may be implicated 
in the pathophysiology of autism (24, 25). There 
is little information about the role of TGF-β2 
in autism. But the available data suggest that 
TGF-β2 has an anti-inflammatory effect on the 
inflammatory process. El-Ansary and Al-Ayadh 
(26) and Vargas et al (27) separately reported that 
the TGF-β2 level increases in autistic children. 
The purpose of the present study is to examine 
whether serum levels of TGF-β1 and TGF-β2 
in autistic patients are altered as compared to 
age-matched normal controls. Furthermore, in 
humans, about 500 mL of CSF is absorbed into 
the blood daily, making blood a suitable source of 
neurodegenerative or neurodevelopmental disease 
biomarkers (28). Recently, researchers have shown 
interest in investigating the relationship between 
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serum or neurological biomarkers and autism 
intensity (29). For example, neuroinflammatory 
biomarkers such as heat shock protein-70, TGF-β, 
interferon-γ, and caspase7 have been shown to be 
correlated with autism intensity (26). However, 
it is unclear whether CNS immune activation 
contributes to the pathology of autism or whether 
it is an epiphenomenon (24). Furthermore, we have 
examined relationships between serum TGF-β1 
and TGF-β2 levels and clinical degree in autistic 
patients.
Material & Methods
Study population and psychological measures 
Thirty-nine autistic children between 7 and 13 
years of age were included in this study population. 
Childhood Autism Rating Scale (CARS) has been 
performed to confirm the diagnosis of autism 
and to assess the severity (30). A 29.5 cut-off 
value was used to diagnose autism. Scores 30–
36.5 and 37–60 indicated mild-to-moderate and 
severe autism, respectively. Moreover, Diagnostic 
Statistical and Manual of Mental Disorders 5th 
Edition (DSM-V) criteria were used to confirm 
autism and differentiate this condition from other 
developmental disorders such as Rett’s disorder, 
Asperger‘s disorder, and childhood disintegrative 
disorder in those children with CARS > 30. All 
participants in both groups were Iranians. Children 
were excluded if they had any known chromosomal 
or neurological disorders. The control group 
included 30 randomly selected, age-matched, 
healthy children with intelligence quotient ranging 
from 90 to 110. All children in the control group 
had no neurological or psychological deficits. 
Informed consents were obtained from parents in 
both groups. Study design was in accordance with 
the tenets of the Helsinki Declaration, as revised 
in 2000, and was approved by the institutional 
review board and ethics committee of Azad 
University of Medical Sciences, Mashhad Branch. 
Questionnaires were used to collect information 
about demographics, past medical history, and 
clinical signs and symptoms of all participants.
Cytokine analysis
Blood samples of autistic and normal children 
were taken by venipuncture from cubital vein at 9 
am, 11:00 a.m. and 12 noon (31). Afterward, cell-
free serums were collected and stored at –70°C 
until the assay. The serum levels of TGF-β1 and 
TGF-β2 were measured using the TGF-β1 and 
TGF-β2 ELISA Kit separately (R&D Systems, 
Inc., Minneapolis, MN, USA), and the samples 
were activated before the assay. The mean detection 
limits were 4.60 pg/mL for TGF-β1 and <7.0 pg/
mL for TGF-β2. All samples were measured in 
duplicate and the respective mean value was 
calculated.
Statistical analysis
Data (i.e. mean age, gender, family history, and 
clinical signs and symptoms of autistic children) 
were analyzed using the Statistical Package for 
Social Sciences (SPSS 18, IBM Corporation, New 
York, NY, USA). The Chi-square test and Student’s 
t-test were performed to analyze qualitative and 
quantitative variables, respectively. For nonnormal 
distributions, the Mann–Whitney test was used. 
Correlation between serum TGF-β level and 
autism severity was determined using Pearson’s 
rank correlation coefficient. A P-value < 0.05 was 
considered statistically significant.
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Results
The demographic and clinical characteristics of 
both groups are summarized in Table 1. Mean 
body mass index (BMI) was 22.85 ± 2.19 kg/m2 
and 20.96 ± 3.25 kg/m2 in autistic children and 
the control group, respectively. No statistically 
significant differences were noted in terms of BMI 
(P = 0.719) and mean age between the 2 groups 
(autism group: 8.54 ± 1.68 years and control group: 
7.9 ±1.4 years, P = 0.330). There were 25 males 
(64.1%) and 14 females (35.9%) in the autism 
group. Clinical examination of autistic children 
revealed that communication problems (40%), 
poor concentration/attention deficit (40%), and 
hyperactivity (33%) were the most common signs 
of these children. Prematurity was noted in the 
past medical history of 5% of patients with autism. 
Based on CARS, 10 children (25.6%) had mild-
to-moderate autism and 29 children (74.4%) were 
diagnosed with a severe form of this condition 
(Table 1).
As shown in Figure 1(a), the mean concentration 
of TGF-β1 in children with autism (25.30 ± 
6.54p g/mL) was significantly (P < 0.0001) lower 
compared to those in the control group (35.09 ± 
9.40 pg/mL). In addition, as shown in Figure 1(b), 
the mean concentration of TGF-β2 in children with 
autism (32.35± 7.75 pg/mL) was higher compared 
to those in the control group (30.47± 4.36 pg /mL); 
however, this difference did not reach statistical 
significance (P = 0.218). In mild-to-moderate and 
severe autisms, the mean concentration of TGF-β1 
was 24.93 ± 6.90 pg/mL and 25.45 ± 6.50 pg/
mL, respectively, and it did not show a significant 
difference between the 2 groups. Also, as shown in 
Figure 2(a), there is a positive correlation between 
TGF-β1 concentration and autism severity (r = 
0.415; P = 0.022). Moreover, in mild-to-moderate 
and severe autisms, the mean concentration of 
TGF-β2 was 35.11 ± 9.52 pg/mL and 31.24 ± 6.83 
pg/mL, respectively. TGF-β2 concentration was 
significantly (P = 0.008) higher in those with severe 
autism. Furthermore, as shown in Figure 2(b), 
there is a negative correlation between TGF-β2 
concentration and autism severity (r = ̶0.412; P = 
0.023). 
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Table 1. Comparison of demographic and clinical data as well as abnormalities in CT-scans between autism (n = 39) and control (n = 
35) groups
Variables Autism group Control group p-value
Mean age(Years) 8.54 ± 1.68 7.9 ±3.1 NSa
Gender (boys/girls) 25/14 20/15 NS
BMI (kg/m2) 22.85 ± 2.19 21.14 ± 2.45 NS
Age of diagnosis 2.8 – –
Severity Severe 29(74.4%) – –
Mild/moderate 10(25.6%) – –
Obstetric complications 4(25%) 6(37.5%) NS
Another disease 8(20.5%) 2(5.7%) NS
Family history 8(20.5%) 0(0.0%) 0.008
Epilepsy 12(30.8%) 0(0.0%) 0.001
Hypoxia 3(7.7%) 0(0.0%) NS
Abnormal CT-scan 1(2.6%) 0(0.0%) NS
aNot signi
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Discussion
In this study, TGF-β1 level was significantly lower 
in autistic children compared to the control group. 
Also, our results show that the mean concentration 
of TGF-β2 in children with autism was higher 
compared to that in the control group. However, 
it did not show any significant difference with 
the control group. A few previous studies have 
evaluated the correlation between TGF-β1 and 
TGF-β2 levels and autism severity (8, 25, 26). 
Similar to previous findings, results of the present 
study show decreased levels of TGF-β1 in blood 
samples from individuals with ASDs. However, 
Vargas et al (27) and El-Ansary and Al-Ayadh (26) 
have, respectively, reported an increased level of 
TGF-β1 and TGF-β2 in the brain of autistic patients 
compared to normal individuals. The nervous and 
immune systems communicate with each other 
through multiple neuroanatomical and secretory 
routes, in addition to the molecular mechanisms 
(15, 24). Pathophysiological changes may occur 
due to the imbalance of the neuroimmune axis 
associated with neurodevelopmental diseases 
such as autism (27). TGF-β1 has been shown to 
play a key role in early CNS development and 
during brain development, which is essential in 
the regulation of early CNS development such as 
astrocyte differentiation, synaptogenesis, neuronal 
migration in the cerebral cortex, neuronal survival, 
neuronal death, microgliosis control, wound 
healing, and immunosuppression (27). These 
findings are in agreement with the hypothesis 
that reduced levels of this cytokine may lead to 
an inappropriate regulation of immune responses, 
and hence the development of neuroinflammation 
disorders such as ASDs. However, it has not 
been shown that whether reduction of TGF-β1 is 
a primary cause of autism or simply a secondary 
reflection of this condition.
Our results demonstrate a mild increase in mean 
concentration of TGF-β2; however, this increase did 
not reach statistical significance. It should be noted 
that, although TGF-β2 may have a role to play in 
brain injury and some neuroinflammations, it has 
been illustrated that TGF-β2 is often considered 
as an anti-inflammatory and wound-healing 
molecule. It has been proposed that enhanced 
TGF-β2 expression may play a role in promoting 
Fig 2.
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inflammation in brain injury associated with autism 
(32). Therefore, TGF-β2 is an immunomodulatory 
cytokine that has different functions based on its 
microenvironment.(33). Generally, TGF-β plays 
a dual role in the inflammation phase by exerting 
proinflammatory effects during the early stages 
and contributing to the resolution of inflammation 
and anti-inflammatory effects in later stages (32). 
We could not confirm the correlation between 
increase in the serum level of TGF-β2 and 
neuroinflammations in autistic children. However, 
controversies remain about the role of TGF-β2 and 
autism.
Despite the large amount of research, it is still 
poorly understand why some of autistic children 
have a mild or severe score in behavioral findings. 
Also, we do not know what leads to certain changes 
to symptoms from those commonly known and 
the reason for the worsening of behavioral scores, 
while they have been calm throughout. Cytokine 
abnormality has been reported as a trigger of events 
leading to autism (14, 34). We found that reduced 
levels of TGF-β1 in autistic children are correlated 
to dysregulation of autism intensity. Our results 
have shown that there is a positive correlation 
between TGF-β1 concentration and autism 
severity. On the other hand, other factors such as 
defects in regulatory T-cell (T.reg) development 
may explain the decreased levels of TGF-β1 in 
the sera and the brain. T.regs are responsible for 
TGF-β1 production, self-tolerance, and immune 
homeostasis. TGF-β1 is required for the suppressive 
function of T.regs (35). The increased level of 
TGF-β in brain tissue may be an outcome of brain 
inflammation (20, 27). However, the relationship 
between CNS and peripheral TGF-β is unclear, 
and all these studies are in agreement that TGF-β 
dysregulation may have a role to play in ASDs 
(24). Many reports indicate that TGF-β1 plays a 
crucial role in the regulation of neurosurvival and 
neurodevelopmental function and limitiing the 
production of IL-2, IFN-ɣ, and TNF, all of which 
can act together to orchestrate the repair processes 
in CNS (1, 28). In fact, TGF-β1 plays a Janus-
like dual role in the regulation of immune and 
inflammatory responses. Under normal conditions, 
TGF-β1 is secreted from microglia, to inhibit 
the neuroinflammation process in brain. But 
under inflammatory conditions, such as autism, 
TGF-β1, which is involved in inflammation, 
apoptosis, neurodegeneration, and other brain 
injuries, is secreted from different cell types 
(32). Thus, TGF-β1 is a multifunctional cytokine 
that depends on the location and surrounding 
milieu for its functions. In cases where a direct 
correlation between TGF-β1 and severity of autism 
is found, the TGF-β1 inflammatory pathway may 
be predominant in comparison to its suppressive 
role. Thus, there is a prevalence of a strong 
neuroinflammatory condition in children at a 
severe stage.
In conclusion
according to the results of this study, lower TGF-β1 
was found to be correlated with more severe 
behavioral scores in ASD children. In addition, 
there was a positive correlation between TGF-β1 
concentration and autism severity. An increased 
serum level of TGF-β2was also observed in ASD 
children compared to the control group, but the 
difference was not significant between the 2 groups. 
Furthermore, there was a negative correlation 
between TGF-β2 concentration and autism severity. 
Dysregulations of these cytokine levels were 
associated with severity level in our patients. The 
neurological consequences of cytokine imbalances 
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during early stages of brain development can lead 
to behavioral abnormalities in autistic children. 
Because autism is a multifactorial disorder, cytokine 
elevation cannot be considered as the only factor 
responsible for autism susceptibility. Considering 
the influence of serum levels of TGF-β1 and 
TGF-β2 on the intensity of autism, further studies 
are required to determine the effects of decreased 
levels of these cytokines. More importantly, due 
to the small sample size, we believe the findings 
of the present study should be confirmed through 
conducting studies based on a larger number of 
patients. Undoubtedly, more findings should be 
taken into account in the assessment of autism 
and in understanding the underlying clinical 
and molecular mechanisms of this disorder. The 
CARS criteria and other clinical findings related 
to cytokine variation in different groups must 
be evaluated separately. Also, postmortem and 
normal newborn infant’s cytokine determinations/
assays may help enhance our understanding of the 
neuroscience behind autism.
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